New COVID-19 pills expand at home treatment options
The FDA authorized Pfizer Paxlovid for patients 12 and older at high risk of hospitalization and Merck molnupiravir for adults with early symptoms and high hospitalization risk. Paxlovid may become preferred due to stronger benefits and milder side effects. molnupiravir carries pregnancy risks and should be used only when others are unavailable.
MENTIONED IN THIS ARTICLE
Washington
USS
Pfizer
Merck
FDA
How to Make and Keep New Year Resolutions
Advice on choosing a meaningful resolution for 2022 and creating a practical plan. Start small, foresee obstacles, and steadily progress. For quitting smoking, consult a health care provider, consider cessation aids, and use resources like the Kansas Quit line and Imh.org for personalized support.
MENTIONED IN THIS ARTICLE
Kansas
Imh.org
Also Mentioned on This Page
U.S
By Matthew Perrone
The
Food and Drug Administration
Ayn
Merck & Co
By Allison Koonce
LMH Health Family